Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma

Affiliations

• ¹ Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ² Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ⁴ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
• ⁵ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ⁶ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Pathology, AC Camargo Cancer Center, São Paulo, Brazil.
• ⁷ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ⁸ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ⁹ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
• ¹⁰ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center and Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USA.
• ¹¹ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ¹² Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ¹³ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ¹⁴ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ¹⁵ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: [email protected].